Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.28 USD
−18.80 M USD
0.00 USD
60.91 M
About MEDICENNA THERAPEUTICS CORP
Sector
Industry
CEO
Fahar Merchant
Website
Headquarters
Toronto
Founded
2015
FIGI
BBG00HNJW3K1
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MDNAF is 1.18 USD — it has increased by 2.61% in the past 24 hours. Watch Medicenna Therapeutics Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Medicenna Therapeutics Corp. stocks are traded under the ticker MDNAF.
MDNAF stock has fallen by −4.84% compared to the previous week, the month change is a 2.61% rise, over the last year Medicenna Therapeutics Corp. has showed a 308.30% increase.
We've gathered analysts' opinions on Medicenna Therapeutics Corp. future price: according to them, MDNAF price has a max estimate of 5.99 USD and a min estimate of 1.78 USD. Watch MDNAF chart and read a more detailed Medicenna Therapeutics Corp. stock forecast: see what analysts think of Medicenna Therapeutics Corp. and suggest that you do with its stocks.
MDNAF reached its all-time high on Dec 28, 2020 with the price of 6.84 USD, and its all-time low was 0.15 USD and was reached on Nov 1, 2023. View more price dynamics on MDNAF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MDNAF stock is 4.27% volatile and has beta coefficient of 1.79. Track Medicenna Therapeutics Corp. stock price on the chart and check out the list of the most volatile stocks — is Medicenna Therapeutics Corp. there?
Today Medicenna Therapeutics Corp. has the market capitalization of 92.79 M, it has decreased by −1.06% over the last week.
Yes, you can track Medicenna Therapeutics Corp. financials in yearly and quarterly reports right on TradingView.
Medicenna Therapeutics Corp. is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
MDNAF earnings for the last quarter are −0.04 USD per share, whereas the estimation was −0.05 USD resulting in a 23.08% surprise. The estimated earnings for the next quarter are −0.04 USD per share. See more details about Medicenna Therapeutics Corp. earnings.
Medicenna Therapeutics Corp. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MDNAF net income for the last quarter is −3.08 M USD, while the quarter before that showed −2.66 M USD of net income which accounts for −15.80% change. Track more Medicenna Therapeutics Corp. financial stats to get the full picture.
No, MDNAF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 23, 2024, the company has 16.00 employees. See our rating of the largest employees — is Medicenna Therapeutics Corp. on this list?
Like other stocks, MDNAF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Medicenna Therapeutics Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Medicenna Therapeutics Corp. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Medicenna Therapeutics Corp. stock shows the sell signal. See more of Medicenna Therapeutics Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.